Combo Drug Glyxambi Now Available – One Pill, One Co-pay

Combo Drug Glyxambi is a combination of empagliflozin and linagliptin in a tablet form for adults with type 2 diabetes. Both empagliflozin, an SGLT-2, and linagliptin, a DPP-4 inhibitor, are already on the market separately. Glyxambi’s main benefit is combining two different diabetes drugs into a single pill (in this case, Tradjenta and Jardiance) with one co-pay. — diaTribe